

Index

a

- adoptive T-cell therapy 352–353
- alternative splicing
 - auxiliary regulatory element 139
 - controlled splicing in *S. cerevisiae* 145
 - and disease 144
 - events in mammalian transcripts 138
 - mechanisms 137
 - and nonsense mediated decay 143
 - regulation mechanism 140
 - transcription-coupled alternative splicing 142
- antibodies 318
- antimicrobial peptides 225
- aptamers 181, 198, 262, 267
- aptazyme-regulated expression devices (aREDs) 199, 205
- array synthesis 8, 10
 - gene assembly on 8

b

- bacterial microcompartments (BMCs) 283–284
- Biobrick-like assembly strategy 337
- BioBricks Foundation (BBF) 393
- biogenesis 282, 289
- biological chassis 50
- Biological Innovation for an Open Society (BIOS) 393
- biological technologies
 - array synthesis 8, 10
 - genetic instruction sets 10
 - Moore's Law 5–6
 - other technologies 6

- pricing improvements in 7–8
- productivity improvements in 3, 5
- BMCs *see* bacterial microcompartments (BMCs)

c

- carbohydrate mimicking peptides (CMPs) 225
- carbon catabolite repression 115
- CARs 351
- catabolic BMCs 283
- cell-free protein synthesis (CFPS) 311
 - advantages for cell-free biology 310
 - antibodies 318
 - future aspects 321
 - genetic circuit optimization 321
 - glycosylation 316
 - in vitro* genetic circuits 321
 - membrane proteins 318–319
 - non-canonical amino acids 316
 - prokaryotic platforms 311
 - protein production and screening 317, 320
 - trends 312, 314
- cellular chassis 50
- cellular immunotherapy
 - CAR for adoptive T-cell therapy 352
 - generation of safer T-cell therapeutics 359
 - immune-system 352
 - T-cell therapeutic function 357
- CFPS *see* cell-free protein synthesis (CFPS)
- chimeric antigen receptors (CARs) 351–352

- Chinese hamster ovary (CHO) 314
 - circular polymerase extension cloning (CPEC) 334
 - comparative genomics 56, 64
 - context-dependent assembly (CoDA) 37
 - controlled splicing in *S. cerevisiae*
 - alternative splicing 145
 - function of 147
 - regulated splicing 146
 - core promoter 110
 - CPEC *see* circular polymerase extension cloning (CPEC)
 - CRISPR/Cas9 system 63
 - CRISPR-enabled trackable genome engineering (CREATE) 27
- d**
- De novo organelle 295
 - directed evolution 341
 - DNA assembly methods
 - BioBrick system 334
 - circular polymerase extension cloning 334
 - Golden Gate 334
 - homologous recombination 333
 - pathway libraries 335
 - polymerase extension 333
 - DNA-binding proteins
 - dimers or tetramers 250
 - TAL-DNA binding domains 249
 - zinc-finger domains 248–249
 - DNA guided assembly 255
 - DNA-guided programming
 - applications 253–254
 - DNA program
 - number of scaffold repeats 252
 - spacers 250
 - spatial position of biosynthetic enzymes 251
 - target site arrangement 253
 - DNA scaffold
 - applications of 253–254
 - binding proteins 247
 - biosynthetic applications 242
 - biosynthetic enzymes 239–240
 - program 250
 - vs. protein and RNA 241
 - DNA sequencing 3, 5–7
 - DNA synthesis 3, 8
 - productivity of 4
 - DNA-target site 241
 - double-stranded DNA (dsDNA) 3, 10
- e**
- E. coli* genome 51
 - E. coli* system 311
 - encapsulins 291–292
 - ePathBrick system 338
 - eukaryotic platforms 312
 - European Academies Science Advisory Council 390
 - exons 132, 134
- f**
- functional peptides
 - binders 220
 - labeling-enzymes 221
 - protease cleavage sites 222
 - reactive peptides 223
 - fusion protein 245
- g**
- gender equality 391
 - gene design
 - alternative splicing in mammals 137
 - controlled splicing in *S. cerevisiae* 145
 - elements of mammalian and budding yeast pre-mRNAs 133
 - influence of introns 152
 - nuclear pre-mRNA splicing in mammals 132
 - self splicing introns 136
 - splicing and synthetic biology 150
 - splicing in yeast 135
 - splicing regulation by riboswitches 147, 149
 - split genes 131
 - tRNA splicing 137
 - gene essentiality 55
 - gene synthesis 9
 - genetic circuit optimization 321
 - genetic diversity-generating factors 59
 - genetic engineering 386

- genetic engineering, T-cell therapeutic function 357
- genome reduction
 - comparative genomics 64
 - gene essentiality 66
 - MG1655 68
 - MGF-01 67
 - streamlined-genome strains 67
- genome transplantation 83, 85
- Gibson assembly method 335
 - acetate utilization 335
 - BglBrick-style cloning 337
 - gene cassette 335
 - violacein biosynthetic pathway 337
- glycosylation 316
- Golden Gate assembly method 334
- governance 395
- green biotechnology 386
- h**
- Halothiobacillus neapolitanus* 286
- helper functions, in synthetic biology 83
 - building blocks and structures with DNA 87
 - energy 91
 - gene ontology 86
 - information 96
 - space management 92
 - time 95
- homologous recombination process 34, 39
- i**
- ICE 313
- immunostimulatory therapies 352
- immunosuppressive therapies 352
- information technology 387
- insect cell extract (ICE) 313
- insertion sequences (ISs) 57
- International Open Facility Advancing Biotechnology (BioFab) 393
- introns 132
- isothermal assembly 265
- l**
- Leishmania tarentolae* extract 314
- lipid-based organelles 292
- localizing metabolic enzymes 267
- L-threonine 242, 245
- m**
- master function, in synthetic biology 85
- Maxwell's demon 96
- MCS *see* multi-cloning site (MCS)
- membrane proteins 318–319
- metabolic engineering 267–268
- mevalonate 246–247
- minimal genome 51
- minimum genome factory 01 (MGF-01) 67
- mitochondrion 293
- modified natural promoters," 116–117
- Moore's Law 5–6
- mRNA degradation 203
- multi-cloning site (MCS) 332
- multiplex automated genome engineering (MAGE) 27
- n**
- nanotechnology 387
- naturally evolved minimal genomes 55
- natural RNA 261–262
- natural yeast promoters
 - regulated promoters," 113–115
- ncRNA *see* non-coding RNA (ncRNA)
- non-canonical amino acids 316
- non-coding RNA (ncRNA) 193, 197
- non-homologous end joining (NHEJ) 35, 38–39
- nuclear pre-mRNA splicing
 - catalytic mechanism 132
 - exons 132, 134
 - introns 132
 - spliceosome 132
- nucleosomes 112
- o**
- oligomerized pool engineering (OPEN) 37
- oligonucleotides (oligos) 3, 7
 - array-synthesized 8
- oligonucleotide-triggered RNAi switches 173

p

- pathway engineering 334
- pathway libraries
 - Biobrick-like assembly strategy 337
 - chromosomal integration 339
 - Gibson assembly method 335
 - plasmid assembly 340
- pathway optimization 335, 337
- pathways 331
- peptides
 - antimicrobial 225
 - epitopes 224
 - functional 220
 - mimotopes 224
 - permissive sites in proteins 218
 - pharmaceutically relevant
 - functions 223
 - protein engineering 218
- pharmaceutically relevant peptides
 - antimicrobial 225
 - epitopes 224
 - mimotopes 224
- plasmid assembly
 - iterative multi-step optimization
 - libraries 341
 - one-step optimization libraries 340
- pre-initiation complex (PIC) 111
- primary targeted deletions
 - defense systems 57
 - genes with unknown and exotic
 - functions 58
 - genetic diversity-generating
 - factors 59
 - insertion sequences (ISs) 57
 - prophages 57
 - redundant and overlapping
 - functions 59
 - repeat sequences 58
 - virulence factors and surface
 - structures 58
- prokaryotic platforms
 - B. subtilis* platform 312
 - Chinese hamster ovary cell
 - extract 314
 - E. coli* extract 311
 - eukaryotic platforms 312
 - insect cell extract 313
 - Leishmania tarentolae* extract 314
 - Streptomyces* platform 312
 - wheat germ extract 313
 - Yeast extract 313
- promoter 110
- 1,2-propanediol 247
- 1,2-propenediol 246
- prophages 57
- protein-based organelles
 - bacterial microcompartments 283
 - biogenesis 289
 - chemical environment 288
 - Citrobacter freundii* 288
 - minimal system 290
 - permeability 287
- protein scaffold 224, 242
- protein-triggered RNA switches 174
- public perceptions
 - in Austria 379
 - civil society groups 384
 - in European union 379
 - in Germany 381
 - in Netherlands 382
 - in United Kingdom 383
 - in U.S. 377

r

- RBS *see* ribosomal binding sites (RBS)
- reactive peptides 223
- Rec E/T system 17
- recombinant technology 269
- recombinases 42
- recombineering substrate 17–18
- recombineering systems 17
- λ -Red system 17–18
- regulated promoters," 113–115
- regulated splicing 146
- replication fork annealing model 17–18
- repurposing existing organelles 293
- responsible research and innovation (RRI)
 - definitions 389
 - ethics 394
 - European Union 389
 - gender equality 391
 - governance 395
 - open access approach 392
 - science education 392

- societal actors 390
 - stakeholders 391
 - trans*-resveratrol 245–246
 - riboregulators 203
 - ribosomal binding sites (RBS) 331
 - riboswitch(es) 147, 185, 193, 198, 203
 - alternative splicing regulation in
 - eukaryotes 148
 - aptamer domain 147
 - expression platform 147
 - group I intron splicing regulation in
 - bacteria 148
 - ribozyme 183, 199, 204
 - RNA degradation process in *E. coli* 190
 - RNA interference
 - switches 170
 - utility 169
 - RNAi switches
 - applications 175, 177
 - design strategies 171
 - development 170
 - future aspects 177
 - oligonucleotide-triggered 173
 - protein-responsive shRNA
 - switch 176
 - protein-triggered 174
 - rational design 174
 - RNAi pathway 170
 - small molecule-triggered 171
 - RNA scaffolding 242
 - RNA switches
 - aptamers 181
 - complex riboswitches 185
 - expression platform 182–184
 - genetic selection 182
 - rational design 183
 - screening 182
 - transcriptional regulation 184
 - translational regulation 183
 - RNA synthetic biology 207
 - Rock's Law 5
 - RRI *see* responsible research and innovation (RRI)
- S**
- science education 392
 - sDNA (synthetic DNA)
 - cost of 9
 - production methods 11
 - self-splicing introns 136
 - shared DNA 19
 - small molecule-triggered RNAi
 - switches 171
 - spliceosome 132
 - sRNA 195, 197–198
 - streamlined chassis 50
 - streamlined genome *E. coli*.
 - codon re-assignment 70
 - gene function and network
 - regulation 69
 - genome architecture 70
 - mobile genetic elements, mutations
 - and evolution 69
 - testing hypotheses 68
 - streamlining
 - chassis 50
 - E. coli* genome 51
 - genome reduction 64
 - random versus targeted 54
 - selection of deletion targets 55
 - substrate channeling 252
 - suicide genes 360–361
 - Superfunctionalized proteins 227
 - Surveyor nuclease 40
 - SynBio *see* synthetic biology (SynBio)
 - synthetic biology (SynBio) 81, 261
 - applications in health and
 - medicine 363
 - CARs 355
 - cellular therapies 350–351
 - chassis 96
 - chemically inducible caspase-9 361
 - comparator 385–386
 - debates 388
 - engineering definition 81
 - genetic engineering 386
 - genome transplantation 83, 85
 - green biotechnology 385
 - helper functions 86
 - information technology 387
 - inverted cytokine receptors 358
 - master function 85
 - Maxwell's demon 96
 - mechanosensitive channels 97

- synthetic biology (SynBio) (*contd.*)
 - nanotechnology 387
 - new therapeutic paradigm 349
 - perceptions 377
 - replication 85, 87, 94, 96
 - reproduction 85, 87
 - RRI 389
 - T-cell function 358
 - synthetic biology and splicing
 - impact of introns 150
 - splicing control by RNA devices 151
 - Synthetic Biology Open Language (SBOL) 393
 - synthetic hybrid promoters
 - advantage 117
 - bipartite structure of natural promoters 117
 - CRISPR-derived system 121
 - DNA-binding activity 119
 - heterologous transcription factor 119
 - transcription activators 119
 - zinc fingers and TALE 119
 - synthetic Notch (synNotch)
 - receptors 356
 - synthetic organelles
 - in budding yeast 293
 - Citrobacter freundii* 288
 - core design principles 282
 - De novo organelle 295
 - eukaryotes 281
 - lipid-based organelles 292
 - permeability 282
 - prokaryotes 281
 - protein complexes 283
 - structure and function 282
 - synthetic promoters:
 - hybrid promoters," 117–121
 - modified natural promoters," 116–117
 - synthetic riboswitches 181, 183
 - synthetic RNA scaffolds
 - applications 268
 - catalytic roles of 262
 - dynamic 265
 - in vitro* selection 264, 266
 - localizing metabolic enzymes 267
 - in nature 263
 - packaging therapeutics 269
 - recombinant technology 269
 - research tools 266
 - secondary structure 262, 264
 - self-assemble into structure 264–265
- t**
- TAL-DNA binding domains 249
 - targeted deletions
 - architectural studies 56
 - circular DNA-based method 60
 - comparative genomics 56
 - CRISPR/Cas9 system 63
 - E. coli* 59
 - gene essentiality 55
 - homologous recombination of dsDNA 59
 - linear DNA-based method 62
 - naturally evolved minimal genomes 55
 - primary targets 57
 - in silico* models 56
 - strategy for piling deletions 62
 - targeting oligos 19
 - TATA-binding protein (TBP) 111
 - TATA element 111
 - T-cell therapeutic function 357
 - trackable multiplex recombineering (TRMR)
 - barcode identification 26
 - CREATE 27
 - dsDNA recombineering 26
 - experimental procedure 23
 - high throughput sequencing 24
 - library design and construction 19, 21
 - MAGE 27
 - mathematical modeling 26
 - microarray/sequencing analysis 24
 - overview 19–20
 - synthetic DNA cassette 19
 - validation 22
 - transcription activators 112
 - transcription factors 112
 - transcription initiation mechanism 112–113

- transcript stability control (TSC) 189
 anticipating issues 201
 computational design 201
 confounding factor 201
 genetic control mechanisms 189
 model-driven process for metabolic pathway 198
 non-coding RNA 197
 polyadenylation 195
 potential mechanisms 205
 probing experiment 204
 RBS sequestration 203
 RNA degradation process in *E.coli* 190
 secondary structure 196
 structural and non-coding RNA 193
 translation effects 192
 tuning knob 190, 195
 uniformity of 5' and 3' ends 202
 transposase fusions 42
 tRNAs splicing 137
 TSC *see* transcript stability control (TSC)
 tunable trackable multiplex recombineering (T²RMR) 19
- U**
- untranslated region (UTR) 181–182, 185
 upstream activation sequences (UASs) 111
 upstream repression sequences (URSs) 113
 U.S. surveys on public perception
 awareness 377
 vs. Europe 378
 imaging 377
 risk and benefits 377
- risk-benefit tradeoff 378
 technology oversight 378
 vs. UK public dialogue 378
- W**
- wheat germ extract (WGE) 313
- Y**
- yeast extract 313
 yeast promoters
 core promoter 110
 natural, 113–116
 nucleosomes 112
 pre-initiation complex 111
 transcription activators 112
 transcription factors 112
 transcription initiation 112–113
 upstream element 111
- Z**
- zinc-finger domains 248–249
 zinc finger nucleases (ZFN) 36
 zinc finger proteins 33
 CoDA approach 37
 delivery into cells, viral and non-viral methods 41
 genome modification 38
 modular assembly 37
 OPEN selection method 37
 recombinases 42
 Sangamo Therapeutics, Inc. 38
 Surveyor nuclease 41
 transposase fusions 42
 use of CRISPR/Cas9 system 38
 whole exome and next generation sequencing methods 41

